cyclophosphamide + doxorubicin + fluorouracil + methotrexate + prednisolone + vincristine

This is a multi-agent chemotherapy regimen composed of six drugs: cyclophosphamide, doxorubicin (also known as adriamycin), fluorouracil (5-FU), methotrexate, prednisolone, and vincristine. Each component has a distinct mechanism of action targeting cancer cells through different pathways: - Cyclophosphamide is an alkylating agent that crosslinks DNA strands, inhibiting DNA replication and transcription. - Doxorubicin intercalates into DNA and inhibits topoisomerase II, leading to DNA breaks. - Fluorouracil is an antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis. - Methotrexate inhibits dihydrofolate reductase, blocking folic acid metabolism required for nucleotide synthesis. - Prednisolone is a synthetic glucocorticoid with anti-inflammatory and immunosuppressive effects; in oncology it induces apoptosis in certain lymphoid cells. - Vincristine binds to tubulin and disrupts microtubule formation during mitosis. This combination has been studied primarily for advanced or disseminated breast cancer[1][2], but similar regimens have also been used in high-grade non-Hodgkin lymphoma[4] and other malignancies. The regimen aims to maximize tumor cell kill by combining agents with complementary mechanisms while minimizing overlapping toxicities.

Other names

VEMFAH